Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2020

27 - 28 Apr 2020

Virtual Annual Meeting

Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract...

Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA

Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers ( Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA )

High mortality among hospital-acquired COVID-19 infection in patients with...

Dr Arielle Elkrief - University of Montreal Hospital Research Centre, Montreal...

High mortality among hospital-acquired COVID-19 infection in patients with cancer: an observational cohort study ( Dr Arielle Elkrief - University of Montreal Hospital Research Centre, Montreal, Canada )

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with...

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

$Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )$

COM701 as a monotherapy and in combination with nivolumab for various advanced...

Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA

COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours ( Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA )

COVID-19: Using oncology drugs and surgery during the coronavirus pandemic

Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy

COVID-19: Using oncology drugs and surgery during the coronavirus pandemic ( Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy )

TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in...

Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA

TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in patients with COVID-19 ( Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA )

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator...

Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line mTNBC ( Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA )

A first-of-its-kind prospective study of a multi-cancer blood test to screen...

Prof Nickolas Papadopoulos - Johns Hopkins Medicine, Baltimore, USA

A first-of-its-kind prospective study of a multi-cancer blood test to screen and manage 10,000 women with no history of cancer ( Prof Nickolas Papadopoulos - Johns Hopkins Medicine, Baltimore, USA )

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk...

Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer ( Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA )

IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients...

Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia

IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia )

Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated...

Prof Alain Algazi -University of California San Francisco, San Francisco, USA

Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma ( Prof Alain Algazi -University of California San Francisco, San Francisco, USA )

More from ecancer